US 12,303,556 B2
Peptides for treatment and prevention of diabetes and associated disorders
Vincent Marion, Lipsheim (FR)
Assigned to UNIVERSITE DE STRASBOURG, Strasbourg (FR); and INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR)
Appl. No. 17/415,796
Filed by UNIVERSITE DE STRASBOURG, Strasbourg (FR); and INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR)
PCT Filed Dec. 20, 2019, PCT No. PCT/EP2019/086573
§ 371(c)(1), (2) Date Jun. 18, 2021,
PCT Pub. No. WO2020/127904, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 18306794 (EP), filed on Dec. 21, 2018.
Prior Publication US 2022/0133860 A1, May 5, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/10 (2006.01); A61K 38/45 (2006.01); A61K 45/06 (2006.01); A61P 3/10 (2006.01)
CPC A61K 38/45 (2013.01) [A61K 45/06 (2013.01); A61P 3/10 (2018.01)] 10 Claims
 
1. A method of treating diabetes and associated disorders selected from the group consisting of type I diabetes, type II diabetes, insulin resistance, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, hyperglycemia, hyperinsulinaemia and Bardet Biedl syndrome comprising the administration of a peptide to a subject in need of treatment, wherein:
the peptide does not simultaneously comprise methionine, proline and arginine residues;
the peptide adopts a secondary structure which is a helix or an alpha helix;
the peptide has a length from 12 to 60 amino acids; and
wherein the peptide sequence comprises one of the following sequences:
 
 (SEQ ID NO: 27)
 
 
 VECTXXEKXVLAX;
 
 
 
 (SEQ ID NO: 28)
 
 
 VECTXXEKXVLAXLDKXXFLTQLHS;
wherein the residues which are bold and underlined X carry a stapling and is any amino acid derivative suitable for stapling; and
wherein X is any amino acid except M, P and R.